Brief: Kadimastem signs memorandum of understanding with Corestem

Corestemchemon

07/12/2016 14:03

Dec 7 (Reuters) - Corestem Inc: 
    * Kadimastem Ltd - announced signing of memorandum of 
understanding with Korean company Corestem, for broad strategic 
collaboration between companies 
    * Kadimastem - Corestem to be granted exclusive license for 
commercialization of company's ALS, diabetes products in 
Asia-Pacific region 
    * Kadimastem - Kadimastem will become a shareholder of 
Corestem by investing $1m in a similar investment mechanism 
    * Kadimastem - under collaboration agreement, companies will 
conduct clinical trials on Kadimastem's product, astrorx, in 
Korea and Asia-Pacific region 
    * Kadimastem - upon signing final agreement, Corestem will 
invest $7m in Kadimastem 
    * Kadimastem - company plans to commence its phase I/IIA 
clinical trial (safety and efficacy of product in humans) in 
mid-2017 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nPn9G8VSBa 
Further company coverage:  166480.KQ  
 
 ((Bangalore.newsroom@thomsonreuters.com;))